Method of treating genital herpes

Details Method of treating genital herpes Method of treating genital herpes

2011-02-22

2011-02-22

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C424S229100, C424S231100

Reexamination Certificate

active

07893083

ABSTRACT:
The present invention is directed to a method of increasing the time period between outbreaks of genital herpes comprising providing an imidazoquinolinamine formulation, disposing an amount of the imidazoquinolinamine formulation into a first nare of an individual infected with Herpes Simplex Virus type 2, covering at least a portion of the internal surface of the individual's first nare with a portion of the amount of the imidazoquinolinamine in the nare, massaging the portion of the amount of the imidazoquinolinamine into the internal surface of the first nare, disposing the amount of the imidazoquinolinamine formulation into a second nare of the individual, covering at least a portion of the internal surface of the second nare with a portion of the amount of the imidazoquinolinamine in said nare and massaging the portion of the amount of the imidazoquinolinamine into the internal surface of said nare.

REFERENCES:
patent: 3608065 (1971-09-01), Lover et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6147086 (2000-11-01), Brenman
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6361769 (2002-03-01), Tovey
patent: 6491940 (2002-12-01), Levin
patent: 6569435 (2003-05-01), Punnonen et al.
patent: 6576757 (2003-06-01), Punnonen et al.
patent: 6890904 (2005-05-01), Wallner et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2004/0067953 (2004-04-01), Stein et al.
patent: 2004/0136917 (2004-07-01), Mandrea
Arrese, Jorge E., et al., “Dermal Dendritic Cells in Anogenital Warty Lesions Unresponsive to an Immune-Response Modifier,” 2001, pp. 131-134, Journal of Cutaneous Pathology, vol. 28.
Bishop, Gail A., “The Immune Response Modifier Resiquimod Mimics CD40-Induced B Cell Activation,” Mar. 8, 2001, pp. 9-17, Cellular Immunology, vol. 208, Academic Press.
Dahl, Mark V., “Imiquimod: A Cytokine Inducer,” Oct. 2002, pp. S205-S208, J. Am. Acad. Dermatol., vol. 47, No. 4, American Academy of Dermatology, Inc.
Dockrell, D. H., Imiquimod and Resiquimod as Novel immunomodulators, 2001, pp. 751-755, Journal of Antimicrobial Chemotherapy, vol. 48, The British Society for Antimicrobial Chemotherapy.
Gibson, Sheila J., et al., “Plasmacytoid Dendritic Cells Produce Cytokines and Mature in Response to the TLR7 Agonists, Imiquimod and Resiquimod,” 2002, pp. 74-86, Cellular Immunology, vol. 218, Elsevier Science, USA.
Hemmi, Hiroaki, et al., “Small Anti-Viral Compounds Activate Immune Cells Via the TLR7 MyD88-Dependent Signaling Pathway,” Jan. 22, 2002, pp. 196-200, Nature Immunology, vol. 3, No. 2, Nature Publishing Group.
O'Mahony, C., et al., “New Patient-Applied Therapy for Anogenital Warts is Rate Favourably by Patients,” Sep. 2001, pp. 565-570, International Journal of STD & AIDS, vol. 12.
Stanley, M. A., “Imiquimod and the Imidazoquinolones: Mechanism of Action and Therapeutic Potential,” 2002, pp. 571-577, Clinical and Experimental Dermatology, vol. 27, Blackwell Science Ltd.
Clejan, Sanda, et al., “Immune Responses Induced by Intranasal Imiquimod and Implications for Therapeutics in Rhinovirus Infections,” 2005, pp. 457-461, J. Cell, Mol. Med., vol. 9, No. 2.
Gaspari, Anthony A., et al., “Immunotherapy of Basal Cell Carcinoma: Evolving Approaches,” Oct. 2003, pp. 1027-1034, American Society for Dermatologic Surgery, Inc., vol. 29, No. 10, Blackwell Publishing, Inc.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Edition, pp. 170-171, 2007.
Hendeles (Abstract, Selecting a Decongestant, Pharmacotherapy, Nov./Dec. 1993, 13, pp. 129S-134S).
C.J Harrison et al., “Modification of Immunological Responses and Clinical Disease During Topical R-837 Treatment of Genital HSV-2 Infection,” Antiviral Research, 10 (1988), pp. 209-223.
Kathleen J. Smith et al., “Squamous Cell Carcinoma in Situ (Bowen's Disease) in Renal Transplant Patients Treated with 5% Imiquimod and 5% 5-Fluorouracil Therapy,”, Dermatol Surg 2001; 27: pp. 561-564.
Nuria Verdaguer et al., “X-ray Structure of a Minor Group Human Rhinovirus Bound to a Fragment of its Cellular Receptor Protein,” Nature Structural & Molecular Biology, vol. 11, No. 5, May 2004, pp. 429-434.
“Correspondence,” British Journal ofDermatology 2002: 146: pp. 331-344.
E. Stockfleth et al., “Successful Treatment of Actinic Keratosis with Imiquimod Cream 5%: a Report of Six Cases,” British Journal of Dermatology 2001: 144: pp. 1050-1053.
Alicia R. Barba, “An Open Label Safety Study of Topical Imiquimod 5% Cream in the Treatment of Molluscum Contagiosum in Children,” Dermatology Online Journal, Jun. 25, 2006, vol. 7, No. 1, pp. 1-6.
Theresa L. Schroeder, “Squamous Cell Carcinoma in Situ of the Penis Successfully Treated with Imiquimod 5% Cream,” J Am Acad Dermatol, Apr. 2002, vol. 46, No. 4, pp. 545-548.
Robin Marks, “Imiquimod 5% Cream in the Treatment of Superficial Basal Cell Carcinoma: Results of a Multicenter 6-Week Dose-Response Trial,” J Am Acad Dermatol, May 2001, vol. 44, No. 5, pp. 807-813.
Claus Oster-Schmidt, “Imiquimod: A New Possibility for Treatment-Resistant Verrucae Planae,” Arch Dermatol, vol. 137, May 2001, pp. 666-667.
Abstracts, The Journal of Investigative Dermatology, p. 584, Oct. 1989.
SJ Gibson et al., “Oral R-837 Induces a Interferon in Cynomologus Mon,” Journal of Interferon Research, vol. 10, issue Suppl. 1, 1990, p. S124.
Michael J. Reiter, et al., “Cytokine Induction in Mice by the Immunomodulator Imiquimod.” Journal of Leukocyte Biology, vol. 55, Feb. 1994, pp. 234-240.
Mark Marsh et al., “Endocytosis in Viral Replication,” Traffic 2000 1: pp. 525-532.
Bart L. Haagmans et al., “Pegylated Interferon-a. Protects Type 1 Pneumocytes Against SARS Coronavirus Infection in Macaques,” Nature Medicine, vol. 10, No. 3, Mar. 2004 pp. 290-293.
Sabine Mihm et al., “Interferon Type I Gene Expression in Chronic Hepatitis C,” Laboratory Investigation (2004) 84, pp. 1148-1159.
Ron A.M. Fouchier et al., “Detection of Influenza A Viruses from Different Species by PCR Amplification of Conserved Sequences in the Matrix Gene,” Journal of Clinical Microbiology, vol. 38, No. 11, Nov. 2000, pp. 4096-4101.
Louis DeTulleo et al., “The Clathrin Endocytic Pathway in Viral Infection,” The EMBO Journal, vol. 17, No. 16, 1998, pp. 4585-4593.
Sara Cherry et al., “Entry is a Rate-Limiting Step for Viral Infection in aDrosophila melanogasterModel of Pathogenesis,” Nature Immunology, vol. 5, No. 1, Jan. 2004, pp. 81-87.
Timothy W. Schacker et al., “Imiquimod 5% Cream Does Not Alter the Natural History of Recurrent Herepes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study”, Antimicrobial Agents and Chemotherapy, vol. 46, No. 10, Oct. 2002, pp. 3243-3248.
David I. Bernstein et al., “Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study,” Clinical Infectious Diseases, 2005:41, pp. 808-814.
PCT International Search Report and Written Opinion dated May 21, 2008 for PCT/US06/14803.
Office Action dated Jun. 20, 2007 for U.S. Appl. No. 10/751,371.
Office Action dated Aug. 19, 2008 for U.S. Appl. No. 11/318,659.
Office Action dated Sep. 16, 2008 for U.S. Appl. No. 11/109,553.

Affiliated with

Also associated with

Rating

Method of treating genital herpes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating genital herpes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating genital herpes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2623627